IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) — Tarsus Prescribed drugs, Inc. (NASDAQ: TARS), whose mission is to deal with unmet wants and apply confirmed science and new know-how to revolutionize remedy for sufferers, beginning with eye care, at present introduced that it’s going to host a dwell webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 8, 2024 to report its second quarter 2024 monetary outcomes and supply a company replace.
Members could entry the webcast right here. A recorded model of the decision shall be obtainable on the web site shortly after the completion of the webcast and shall be archived there for roughly 90 days.
About Tarsus Prescribed drugs, Inc.
Tarsus Prescribed drugs, Inc. applies confirmed science and new know-how to revolutionize remedy for sufferers, beginning with eye care. Tarsus is advancing its pipeline to handle a number of ailments with excessive unmet want throughout a variety of therapeutic classes, together with eye care, dermatology and infectious illness prevention. XDEMVY ® (lotilaner ophthalmic resolution) 0.25% is FDA authorized in the US for the remedy of Demodex blepharitis. Tarsus can also be creating TP-03 as an investigational remedy for the remedy of Meibomian Gland Illness, TP-04 for the remedy of rosacea and TP-05 as an oral pill for the prevention of Lyme illness, all of that are in Part 2.
Media Contact:
Adrienne Kemp
Sr. Director, Company Communications
(949) 922-0801
akemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com